tetano
Editor, Senior Moderator
Vaccine. 2014 Feb 20. pii: S0264-410X(14)00182-0. doi: 10.1016/j.vaccine.2014.02.009. [Epub ahead of print]
Intranasal vaccination with a replication-deficient influenza virus induces heterosubtypic neutralising mucosal IgA antibodies in humans.
Morokutti A1, Muster T2, Ferko B3.
Author information
Abstract
We investigated the cross-neutralising potential of serum and nasal wash samples from volunteers who were intranasally immunised once with a monovalent replication-deficient delNS1-H1N1 influenza virus vaccine (7.7log10TCID50/volunteer). Eight out of twelve (8/12) vaccinees responded to vaccination with a significant increase of antibody levels in serum IgG ELISA, mucosal IgA ELISA, MNA or HAI. Four responders showed delNS1-specific ELISA IgA increases and revealed excellent homosubtypic neutralising activity in serum and mucosal washings (4/4). However, 0/4 of the sera but 3/4 of the nasal washings neutralised also heterosubtypic H3N2 and H5N1 influenza viruses. Depletion experiments proved that IgA but not IgG is responsible for the cross-neutralising activity of the nasal wash sample. Our findings indicate that the induction of virus-neutralising IgA may represent a valuable correlate of cross-protection of intranasal influenza vaccines and that the delNS1 concept constitutes a promising approach to protect humans from seasonal and pandemic influenza threats. Clinical trial registration: NCT00724997.
Copyright ? 2014. Published by Elsevier Ltd.
KEYWORDS:
Cross-reactive antibodies, Heterologous immunity, Nasal wash IgA, Single intranasal immunisation, delNS1 influenza virus vaccine
PMID:
24560674
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24560674
Intranasal vaccination with a replication-deficient influenza virus induces heterosubtypic neutralising mucosal IgA antibodies in humans.
Morokutti A1, Muster T2, Ferko B3.
Author information
Abstract
We investigated the cross-neutralising potential of serum and nasal wash samples from volunteers who were intranasally immunised once with a monovalent replication-deficient delNS1-H1N1 influenza virus vaccine (7.7log10TCID50/volunteer). Eight out of twelve (8/12) vaccinees responded to vaccination with a significant increase of antibody levels in serum IgG ELISA, mucosal IgA ELISA, MNA or HAI. Four responders showed delNS1-specific ELISA IgA increases and revealed excellent homosubtypic neutralising activity in serum and mucosal washings (4/4). However, 0/4 of the sera but 3/4 of the nasal washings neutralised also heterosubtypic H3N2 and H5N1 influenza viruses. Depletion experiments proved that IgA but not IgG is responsible for the cross-neutralising activity of the nasal wash sample. Our findings indicate that the induction of virus-neutralising IgA may represent a valuable correlate of cross-protection of intranasal influenza vaccines and that the delNS1 concept constitutes a promising approach to protect humans from seasonal and pandemic influenza threats. Clinical trial registration: NCT00724997.
Copyright ? 2014. Published by Elsevier Ltd.
KEYWORDS:
Cross-reactive antibodies, Heterologous immunity, Nasal wash IgA, Single intranasal immunisation, delNS1 influenza virus vaccine
PMID:
24560674
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24560674